Clinical Trial Update: Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating Odronextamab for relapsed or refractory large B-cell lymphomas before CAR-T therapy; the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma Grade 3b
• High-grade B-cell Lymphoma
• Mediastinal Large B-cell Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Odronextamab (REGN1979) (Odronextamab)

Snippet

Sponsor: University of Washington | Conditions: Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 2 | Status: RECRUITING